Get alerts
Closes in 37 hoursResponses due Fri, Oct 9 at 9:00 AM ET · about 37 hours left
Special noticeFederal buyerSB

precisionFDA cloud-based genomics platform

HEALTH AND HUMAN SERVICES, DEPARTMENT OF, Maryland · FOOD AND DRUG ADMINISTRATION · FOOD AND DRUG ADMINISTRATION
Verified 20 h agoUpdated Oct 7 · Updated
Responses dueFri, Oct 99:00 AM ET · Maryland timeabout 37 hours left
PostedWed, Sep 23No amendments since
Solicitation no.Not statedSAM.gov
Set-asideSBOnly firms holding this status can compete

What the agency is buying

by RFPFinder from the notice; the solicitation governs

The Food and Drug Administration (FDA) intends to award a sole-source Indefinite Delivery Indefinite Quantity (IDIQ) contract to DNAnexus, Inc. for the precisionFDA platform.

Scope

  • Platform access licenses, cloud computing resources (compute, storage, data transfer on AWS), operations and maintenance, security patching, and technical
Small business set-asideSubmission: emailDays to respond: 2

How to get the bid documents

  1. Open the notice on SAM.gov
  2. Read the notice; the source lists no attachments
  3. Submit by email before 9:00 AM ET on Oct 9

The source notice lists no attachments.

Open the original listing on SAM.gov

Details

Place of performance
Rockville, Maryland
Buyer type
Federal
Notice type
Special Notice
Solicitation no.
Not stated
NAICS
NAICS 541714 (Research and Development in Biotechnology (except Nanobiotechnology)): 12 open RFPs
Delivery location
Contractor facility and FDA White Oak Campus, 10903 New Hampshire Avenue, Silver Spring, MD 20993 from notice
Period of performance
08/10/2026 08/09/2030 from notice
Contract type
Firm-Fixed-Price IDIQ from notice
Approved sources
DNAnexus, Inc. from notice
Local presence
Not required
Amendments
None since Sep 23
Contact
Steven Gagnon
Office
FOOD AND DRUG ADMINISTRATION · FOOD AND DRUG ADMINISTRATION
Email
Steven.gagnon@fda.hhs.gov

Not stated in the notice: estimated value. Check the bid documents.

Contact details from the source notice. Contact the buyer only about this solicitation.

Key dates

Wed, Sep 23Posted
Not statedQuestions due
Fri, Oct 9 · 9:00 AM ETResponses due · about 37 hours left Under 14 days

Change log

verified Wed, Oct 7 · 12:30 AM ET
  1. Posted · Special NoticeWed, Sep 23 · 6:32 PM ET
  2. Updated · description text changedWed, Oct 7 · 12:31 AM ET

Change log starts Oct 5, 2026 (tracking began); earlier amendments at SAM.gov are being pulled in.

Report a problem

Notice as published

precisionFDA cloud-based genomics platform

SPECIAL NOTICE INTENT TO SOLE SOURCE Food and Drug Administration (FDA) Office of Acquisitions and Grants Services (OAGS) Acquisition Title: FY26FY30 precisionFDA Platform Indefinite Delivery Indefinite Quantity (IDIQ) Acquisition Identification Number: ODT-2026-132021 NAICS Code: 541714 PSC Code: D319 (Cloud Computing) Set-Aside: Small Business (DNAnexus confirmed SB under NAICS 541714) Contract Type: Firm-Fixed-Price IDIQ Period of Performance: 08/10/2026 08/09/2030 Estimated Value: $33,000,000 Notice: The Food and Drug Administration (FDA), Office of Digital Transformation (ODT), Office of Data Analytics and Research (ODAR), Health Informatics Staff (HIS), intends to award a sole-source Indefinite Delivery Indefinite Quantity (IDIQ) contract to: DNAnexus, Inc. 1975 West El Camino Real, Suite 204 Mountain View, CA 94040 This action is being conducted under the authority of FAR 6.302-1 (Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements), pursuant to 41 U.S.C. 3304(a)(1).

Description of Requirement: The FDA requires continued operations, sustainment, modernization, and cloud support for the precisionFDA platform a FISMA-authorized, secure, cloud-based collaborative research environment for next-generation sequencing (NGS) assay evaluation, genomics and multi-omics research, and regulatory science applications. The platform supports collaboration between FDA researchers and reviewers, as well as external collaborators and sponsors across multiple FDA centers, including CDER, CBER, CDRH, CVM, and CFSAN. Services to be acquired include: Platform access licenses, cloud computing resources (compute, storage, data transfer on AWS), operations and maintenance, security patching, and technical support Continuation of all current precisionFDA capabilities, including immutable files with chain of provenance, file locking, Government-only spaces, Protected spaces, Review spaces, FHIR Stations, Scientific Challenge Framework, and custom data portal development capability Development and maintenance of the precisionFDA High (FISMA High) platform on FDA GovCloud FedRAMP Class C (Moderate) and FISMA High compliance maintenance per NIST SP 800-53 Rev5 Integration support for FDA enterprise systems including the Global Substance Registration System (GSRS) Training, user support, disaster recovery, and business continuity services Place of Performance: Contractor facility and FDA White Oak Campus, 10903 New Hampshire Avenue, Silver Spring, MD 20993 Basis for Sole Source Determination: Comprehensive market research was conducted in accordance with FAR Part 10, evaluating 20 vendors with a detailed assessment of 8 shortlisted vendors against 33 critical capability requirements.

The research conclusively determined that DNAnexus is the only vendor capable of meeting FDA's requirements for Day-1 continuity of the precisionFDA mission on the date of contract award, for the following reasons: Only vendor with zero capability gaps: DNAnexus is the only vendor that scored fully across all 33 assessed capabilities. No alternative vendor can replicate on Day 1 the precisionFDA capabilities of immutable files with chain of provenance, file locking, Government-only spaces, Protected spaces, Review spaces, FHIR Stations, the Scientific Challenge Framework, or custom data portal development capability. Unique secure external collaboration capability: DNAnexus is the only platform provider able to facilitate secure FDA-sponsored scientific challenges and controlled communication with industry sponsors, vendors, academic researchers, and international regulatory partners while maintaining regulatory-grade confidentiality controls, data segregation, audit trails, and compliance features.

Institutional knowledge and validated workflows: FDA has invested over seven years in developing, validating, and documenting bioinformatics workflows on the precisionFDA platform. Over 300 FDA scientific reviewers, bioinformaticians, and research scientists have been trained on the platform. The application library includes 100+ versioned apps.

Migration to an alternative platform would require complete revalidation and an estimated $14.7M full rebuild.

FedRAMP and FISMA compliance: DNAnexus holds FedRAMP Class C (Moderate) authorization (Cert ID FR1814557199, confirmed June 18, 2026) and FISMA Moderate ATO (FDA-sponsored). DNAnexus is actively enrolled in the PRISM High-Impact Platform Pilot (March 2026) providing a structured pathway to FedRAMP High authorization, with a parallel FISMA High ATO track to support the precisionFDA High platform.

Small Business: DNAnexus is confirmed as a Small Business under NAICS 541714 (~277 employees; 1,000-employee size standard).

Response Instructions: This notice is not a solicitation and does not commit the Government to award a contract. No award will be made solely on the basis of responses to this notice. Interested parties who believe they are capable of meeting the Government's requirements in their entirety may submit a written capability statement to the Contracting Officer no later than 15 calendar days from the date of this notice.

Capability statements will be evaluated to determine whether full and open competition should be conducted in lieu of a sole-source award. Capability statements must address, at a minimum, the vendor's ability to provide Day-1 continuity of all current precisionFDA capabilities, FedRAMP Class C (Moderate) authorization status, and a demonstrated pathway to FISMA High authorization. Responses must be submitted electronically to: Steven Gagnon, Contracting Officer Email: [email on the source notice] Allison Meads, Contract Specialist Email: [email on the source notice] Subject Line: Capability Statement precisionFDA IDIQ Sole Source Notice, ODT-2026-132021 Telephone responses will not be accepted.

The Government is not responsible for any costs incurred in preparing a response to this notice.

Point of Contact: Steven Gagnon, Contracting Officer Food and Drug Administration, Office of Acquisitions and Grants Services Email: [email on the source notice] Allison Meads, Contract Specialist Email: [email on the source notice]

Similar Food and Drug Administration awards · NAICS 541714

USAspending.gov, last 36 months

2 awards matched · tier 2: Food and Drug Administration + NAICS 541714; nothing from this office. Most recent:

  • Sep 10RESEARCH CENTER PHARMACEUTICAL ENGINEERING GMBHNEXT GENERATION PROCESS DEVELOPMENT AND QUALITY CONTROL IN PROTEIN LYOPHILIZATION USING MECHANISTIC AND AI APPROACHES75F40126C00098 · Food and Drug Administration · ends Sep 9, 2028$734K
Pro

Pro shows every award with the recipient, amount, period and a link to the award record, plus a CSV export. $39/mo.

Sign in or upgrade

Awards updated Tue, Oct 6, 2026 · 6:47 AM ET.

This contracting office

3 other open notices from this office · buys mostly IT & Software

Similar open RFPs

same NAICS 541714

Listing collected from SAM.gov. Always confirm requirements in the original solicitation before you bid.

Alert meView on SAM.gov